Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib in Advanced Non-squamous NSCLC
NCT02356991Phase 2Suspended
- Sponsor
- Hengrui
- Start
- Dec 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Famitinib with Placebo (2 arms). Primary endpoint: Progression Free Survival at 1.5 years. Started Dec 2014; status: suspended.
02
Drugs
famitinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02356991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356991.